🚨 New Pharmacotherapy for Obstructive Sleep Apnoea 🌙💊

In a landmark Phase 2 trial published in The Lancet, sultiame— a carbonic anhydrase inhibitor—showed dose-dependent reduction in AHI and improved nocturnal oxygenation in adults with moderate–severe OSA.

💡 Key insights:

• 298 participants across 5 European countries

• 200 mg daily delivered the best efficacy-to-tolerability balance

• Benefits most notable in sleepy phenotypes (ESS >10)

• Mild, dose-related paraesthesia most common AE

🔬 A promising step toward precision sleep medicine and pharmacologic options for patients who struggle with CPAP.

🌬️ Better breathing by night → brighter cognition by day.

📖 Lancet, 2025 — FLOW Study (Randerath et al.)